Cargando…
The discovery of rivaroxaban: translating preclinical assessments into clinical practice
Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations of traditional anticoagulants. Rivaroxaban is an oral, direct factor Xa inhibitor that inhibits free and clot-bound...
Autores principales: | Kubitza, Dagmar, Perzborn, Elisabeth, Berkowitz, Scott D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838992/ https://www.ncbi.nlm.nih.gov/pubmed/24324436 http://dx.doi.org/10.3389/fphar.2013.00145 |
Ejemplares similares
-
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016) -
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013) -
Laboratory assessment of rivaroxaban: a review
por: Samama, Meyer Michel, et al.
Publicado: (2013) -
Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction: In Vitro and In Vivo Studies
por: Perzborn, Elisabeth, et al.
Publicado: (2015) -
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
por: Solms, Alexander, et al.
Publicado: (2019)